| __timestamp | Vertex Pharmaceuticals Incorporated | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60987000 | 3243000 |
| Thursday, January 1, 2015 | 125542000 | 2472000 |
| Friday, January 1, 2016 | 210460000 | 2548000 |
| Sunday, January 1, 2017 | 275119000 | 19623000 |
| Monday, January 1, 2018 | 409539000 | 30421000 |
| Tuesday, January 1, 2019 | 547758000 | 32793999 |
| Wednesday, January 1, 2020 | 736300000 | 28304000 |
| Friday, January 1, 2021 | 904200000 | 620000 |
| Saturday, January 1, 2022 | 1080300000 | 755000 |
| Sunday, January 1, 2023 | 1262200000 | 1322000 |
| Monday, January 1, 2024 | 1530500000 |
Unlocking the unknown
In the evolving landscape of biotechnology, understanding cost structures is crucial. Over the past decade, Vertex Pharmaceuticals Incorporated has seen a staggering 1,970% increase in its cost of revenue, reflecting its aggressive expansion and investment in cutting-edge therapies. Starting from a modest $61 million in 2014, Vertex's cost of revenue soared to approximately $1.26 billion by 2023. This growth underscores Vertex's commitment to innovation and market leadership.
Conversely, Viridian Therapeutics, Inc. presents a contrasting narrative. Despite fluctuations, its cost of revenue remained relatively stable, peaking at $32.8 million in 2019 before dropping significantly. This stability, coupled with a recent decline, suggests a strategic pivot or operational efficiency.
These insights highlight the diverse strategies within the biotech sector, where companies like Vertex focus on scaling, while others like Viridian may prioritize efficiency or niche specialization.
Cost Insights: Breaking Down Merck & Co., Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Pfizer Inc. and Viridian Therapeutics, Inc.
Amgen Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Vertex Pharmaceuticals Incorporated and Pharming Group N.V.
Vertex Pharmaceuticals Incorporated vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Vericel Corporation
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Catalent, Inc. vs Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.